Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

The man opens the door. The concept of mystery or new opportunities or the path to the future.

GLP-1

Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.

January 27, 2026

2 min read

Tristan Manalac

Composite contemporary collage statue of justice themis femida on the background of the target as the concept and idea of justice and law. High quality photo

Legal

CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud

Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.

January 27, 2026

2 min read

Tristan Manalac

The Westin St. Francis in San Francisco, home of the J.P. Morgan Healthcare Conference.

JPM

JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute

With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.

January 27, 2026

6 min read

Annalee Armstrong

Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.

Manufacturing

Big Pharma Tight-Lipped on Details of API Stockpile Deals

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.

January 27, 2026

4 min read

Nick Paul Taylor

Illustration of woman checking progress on project

Opinion

FDA Inspections Should Not Be Source of Stress

True inspection readiness is about the integrity of a company’s entire system.

January 27, 2026

5 min read

Greg Walker

Hand Serving Stack Of Dollar coin Bills On Platter To A Businessman

Mergers & acquisitions

Revolution Knows Its Worth as Merck Backs Off—For Now

Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.

January 26, 2026

4 min read

Annalee Armstrong

Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.

Duchenne muscular dystrophy

Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

January 26, 2026

2 min read

Dan Samorodnitsky